For research and educational purposes only. Not intended for human consumption.
TB-500
Well Researched- •Phase I safety data up to 1260mg doses
- •2024 IBD/intestinal healing research
- •Metabolite (Ac-LKKTE) activity clarified
Thymosin Beta-4 Fragment (Ac-LKKTETQ)
Overview
What is TB-500?
TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) corresponding to the active actin-binding region (positions 17-23) of thymosin beta-4. Originally developed for veterinary use in horses, this fragment retains tissue repair and anti-inflammatory properties while being more stable than the full peptide. Recent 2023-2025 research suggests any wound-healing activity may primarily be due to its metabolite Ac-LKKTE rather than the parent compound itself. Banned by WADA
Key Benefits
Superior systemic tissue repair, accelerated healing of muscles, tendons, ligaments, and organs. Enhanced cell migration and angiogenesis for comprehensive regenerative effects. Clinical trials on parent TB4 show reduced eye dryness and accelerated wound healing.
Mechanism of Action
Injectable TB-500 provides systemic distribution for whole-body tissue repair. Acts as the principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation. Research indicates pro-angiogenic and anti-inflammatory effects with tissue repair mechanisms.
Molecular Information
Pharmacokinetics
Research Indications
Muscle Regeneration
Accelerated healing of muscle fibers, reduced recovery time from muscle injuries, and enhanced muscle tissue repair through improved cell migration and differentiation.
Tendon & Ligament Healing
Promotes connective tissue repair, reduces scar formation, and improves biomechanical properties of healing tendons and ligaments.
Wound Healing
Enhanced dermal wound closure, improved angiogenesis, and reduced inflammation in both acute and chronic wound healing scenarios.
Research Protocols
Disclaimer: TB-500 is commonly reported with a loading phase (4-6 weeks at 2-2.5mg 2x/week) followed by a maintenance phase (2-4mg every 1-2 weeks). Tapering as symptoms improve is often discussed rather than abrupt discontinuation. This is not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General tissue repair | 2-3mg | 2x weekly | SubQ or IM |
| Serious injury recovery | 4-5mg | 3x weekly | SubQ near injury site |
| Athletic enhancement | 2-3mg | 2x weekly | SubQ |
| Chronic conditions | 3-4mg | 2-3x weekly | SubQ or IM |
| Maintenance | 2mg | 1-2x weekly | SubQ |
| Post-surgical recovery | 3-5mg | 3x weekly | SubQ |
Timing: TB-500 timing is flexible and doesn't require empty stomach. For localized injuries, inject as close to the injury site as possible. For systemic effects, standard subcutaneous injection sites work well.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean work area and hands thoroughly with alcohol
Calculate required BAC water volume using calculator below
Draw calculated BAC water slowly into syringe
Inject BAC water slowly down the side of vial (never directly onto powder)
Gently swirl vial until powder completely dissolves (never shake vigorously)
Store reconstituted solution in refrigerator and use within 28 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White Lyophilized Powder
TB-500 should appear as a white to off-white, fine powder that is evenly distributed in the vial. Proper lyophilization creates a light, fluffy texture.
Clear Solution After Reconstitution
When properly reconstituted with BAC water, TB-500 should form a completely clear, colorless solution with no visible particles or cloudiness.
Proper Vacuum Seal
Vial should have intact vacuum seal with no cracks or damage. The rubber stopper should be secure and show no signs of contamination.
Slight Powder Clumping
Minor clumping during shipping is acceptable if it dissolves completely with gentle swirling. Avoid shaking vigorously.
Colored or Crystalline Powder
Any discoloration (yellow, brown) or crystalline appearance may indicate degradation or contamination. Should appear as fine white powder only.
Persistent Cloudiness
If solution remains cloudy, has floating particles, or shows precipitation after reconstitution, the peptide may be degraded or contaminated.
What to Expect
- •Week 1-2: Reduced inflammation and improved tissue sensation
- •Week 2-4: Accelerated healing rate and improved tissue quality
- •Week 4-8: Maximum tissue repair and regenerative benefits
- •Week 6-12: Continued improvement in tissue strength and function
- •Side effects: Generally minimal, possible injection site reactions
- •Most effective for: Muscle, tendon, ligament, and soft tissue injuries
Side Effects & Safety
Side Effects
- •Use sterile injection technique to prevent infection
- •Mild injection site reactions are normal and temporary
- •Consult healthcare provider if on immunosuppressive medications
- •Not recommended during active cancer treatment
- •Avoid during pregnancy or breastfeeding
- •WADA prohibited - not for competitive athletes
When to Stop
- •Signs of infection at injection site
- •Severe allergic reactions
- •Unusual swelling or pain
- •Flu-like symptoms that persist
- •Any concerning symptoms - consult healthcare provider
References
6 StudiesPhase I Safety Trial (Synthetic TB4)
Human | Up to 1260mg doses | Safety assessment
Early phase I trials of synthetic thymosin beta-4 showed no toxicity or serious adverse events at doses up to 1260 mg, establishing baseline human safety profile.
Inflammatory Bowel Disease Model (2024)
Animal | Intestinal healing | IBD treatment potential
Animal models suggest TB-4 may improve intestinal healing in inflammatory bowel disease and modulate immune responses, supporting anti-inflammatory applications.
Metabolite Activity Research (2023)
In vitro | Ac-LKKTE analysis | Mechanism clarification
2023 study confirmed wound-healing activity previously attributed to TB-500 may actually be due to its metabolite Ac-LKKTE rather than the parent compound itself.
Quick Start Guide
Research Disclaimer
TB-500 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving TB-500 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of TB-500 for any purpose. Consult qualified professionals for any research applications.